Great West Life Assurance Co. Can grew its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 84.6% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,543 shares of the biopharmaceutical company’s stock after buying an additional 2,541 shares during the quarter. Great West Life Assurance Co. Can’s holdings in Agios Pharmaceuticals were worth $285,000 as of its most recent filing with the SEC.
Several other hedge funds have also made changes to their positions in the company. Janney Montgomery Scott LLC raised its stake in shares of Agios Pharmaceuticals by 9.7% in the 2nd quarter. Janney Montgomery Scott LLC now owns 4,820 shares of the biopharmaceutical company’s stock valued at $248,000 after buying an additional 425 shares in the last quarter. Arthur M. Cohen & Associates LLC bought a new stake in shares of Agios Pharmaceuticals in the 2nd quarter worth about $397,000. Public Employees Retirement Association of Colorado grew its holdings in shares of Agios Pharmaceuticals by 5.2% in the 2nd quarter. Public Employees Retirement Association of Colorado now owns 6,504 shares of the biopharmaceutical company’s stock worth $335,000 after purchasing an additional 323 shares during the last quarter. Hamilton Lane Advisors LLC bought a new stake in shares of Agios Pharmaceuticals in the 2nd quarter worth about $2,890,000. Finally, Parametrica Management Ltd bought a new stake in shares of Agios Pharmaceuticals in the 2nd quarter worth about $228,000. Institutional investors own 94.30% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://sportsperspectives.com/2017/09/13/great-west-life-assurance-co-can-acquires-2541-shares-of-agios-pharmaceuticals-inc-agio.html.
In other Agios Pharmaceuticals news, insider Scott Biller sold 2,146 shares of the business’s stock in a transaction dated Friday, July 7th. The stock was sold at an average price of $55.00, for a total transaction of $118,030.00. Following the completion of the transaction, the insider now owns 8,410 shares of the company’s stock, valued at $462,550. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO David P. Schenkein sold 3,000 shares of the business’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $51.18, for a total value of $153,540.00. Following the transaction, the chief executive officer now directly owns 3,000 shares of the company’s stock, valued at approximately $153,540. The disclosure for this sale can be found here. In the last three months, insiders have sold 84,230 shares of company stock valued at $4,943,142. Insiders own 10.55% of the company’s stock.
Shares of Agios Pharmaceuticals, Inc. (NASDAQ AGIO) opened at 66.11 on Wednesday. The firm’s 50-day moving average is $59.33 and its 200-day moving average is $54.04. Agios Pharmaceuticals, Inc. has a one year low of $39.24 and a one year high of $67.74. The company’s market cap is $3.20 billion.
Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.57) by ($0.21). The business had revenue of $11.30 million for the quarter, compared to analyst estimates of $10.68 million. Agios Pharmaceuticals had a negative return on equity of 68.15% and a negative net margin of 502.12%. The firm’s revenue was up 62.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.47) EPS. Analysts expect that Agios Pharmaceuticals, Inc. will post ($7.07) EPS for the current fiscal year.
Several research firms have recently weighed in on AGIO. BidaskClub lowered shares of Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. SunTrust Banks, Inc. reaffirmed a “buy” rating and issued a $80.00 target price (up previously from $68.00) on shares of Agios Pharmaceuticals in a report on Tuesday, August 8th. Needham & Company LLC upped their target price on shares of Agios Pharmaceuticals from $54.00 to $72.00 and gave the stock a “buy” rating in a report on Thursday, August 10th. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and issued a $83.00 target price (up previously from $75.00) on shares of Agios Pharmaceuticals in a report on Thursday, August 10th. Finally, Leerink Swann raised shares of Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $50.00 to $80.00 in a report on Wednesday, August 2nd. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $74.75.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO).
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.